Effect of myo-inositol supplementation on ICSI outcomes among poor ovarian responder patients: A randomized controlled trial - 28/04/20
, Robabeh Ghodssi-Ghassemabadi dBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Purpose |
This study has evaluated the use of myo-inositol supplementation for improving reproductive outcomes in poor responders undergoing intracytoplasmic sperm injection (ICSI).
Methods |
One hundred and twelve poor responder patients were included in the study and randomly categorized into two groups using a permuted block randomization method. Group A included 56 patients who received myo-inositol (4 g) and folic acid (400 μg) daily from one month before starting the ICSI cycle continuing until the ovulation triggering day. Group B included 56 patients consuming only folic acid (400 μg) daily for the same period. The outcome measures were the number of retrieved oocytes, embryo quality, Ovarian Sensitivity Index (OSI: number of oocytes retrieved/total Gonadotropins units × 1000), fertilization, implantation, and ongoing pregnancy rates.
Results |
No significant difference was observed between the two groups regarding the total dose of gonadotropin used, OSI, and the number of total retrieved and mature oocytes. Grad A embryos and fertilization rate were significantly increased in group A. Implantation and pregnancy rates showed statistically insignificant changes.
Conclusion |
Treatment of poor responders with myo-inositol from one month before starting ICSI cycle continuing until ovulation trigger can improve fertilization rate and embryo quality, and may enhance the cumulative pregnancy rate in poor responders.
Le texte complet de cet article est disponible en PDF.Keywords : Myo-inositol, Intracytoplasmic sperm injection, Embryo quality, Fertilization, Reproductive outcomes
Plan
Vol 49 - N° 5
Article 101698- mai 2020 Retour au numéro
Article précédent
- Dual trigger using recombinant HCG and gonadotropin-releasing hormone agonist improve oocyte maturity and embryo grading for normal responders in GnRH antagonist cycles: Randomized controlled trial
- Shymaa S. Ali, Elwany Elsenosy, Gamal H. Sayed, Tarek A. Farghaly, Ahmed A. Youssef, Esraa Badran, Ahmed M. Abbas, Ahmed A. Abdelaleem
- Comparison of process outcomes, clinical symptoms and laboratory values between patients with antepartum preeclampsia, antepartum with persistent postpartum preeclampsia, and new onset postpartum preeclampsia
- Sarah Tran, Joshua Fogel, Shahd Karrar, Peter Hong
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?